

Edgar Filing: EXPRESS SCRIPTS INC - Form 8-K

EXPRESS SCRIPTS INC
Form 8-K
November 08, 2002
81895-1

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report: November 8, 2002

Express Scripts, Inc.

(Exact Name of Registrant as specified in its Charter)

Delaware

0-20199

43-1420563

(State or other jurisdiction
of corporation)

(Commission File No.)

(I.R.S. Employer
Identification No.)

13900 Riverport Drive, Maryland Heights, Missouri

63043

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code: (314) 770-1666

(Former name or former address, if changed since last report)

Item 9. Regulation FD Disclosure

As previously disclosed, on August 6, 2002 Express Scripts, Inc. (the "Company") received a subpoena duces tecum issued by the Defense Criminal Investigative Service (DCIS) of the Office of Inspector General of the Department of Defense. This subpoena sought information pertaining to the

Edgar Filing: EXPRESS SCRIPTS INC - Form 8-K

purchase of Lipitor, a cholesterol-reducing drug, from Parke-Davis, Incorporated, Warner Lambert Company and Pfizer, Inc. for sale to the TRICARE program, a Department of Defense health care program. The Company has recently been advised by DCIS that it is no longer necessary for the Company to respond to this subpoena.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXPRESS SCRIPTS, INC.

Date: November 8, 2002

By: /s/ Barrett A. Toan

Barrett A. Toan
Chairman and Chief Executive Officer